$715 Million is the total value of Casdin Capital, LLC's 35 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 32.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMI | Buy | FOUNDATION MEDICINE INC | $93,640,000 | +128.7% | 685,000 | +31.7% | 13.10% | +81.8% |
| LOXO | LOXO ONCOLOGY INC | $62,453,000 | +50.4% | 360,000 | 0.0% | 8.73% | +19.6% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $40,310,000 | +26.3% | 635,000 | +82.5% | 5.64% | +0.5% |
| SAGE | SAGE THERAPEUTICS INC | $39,133,000 | -2.8% | 250,000 | 0.0% | 5.47% | -22.7% | |
| MYOK | Buy | MYOKARDIA INC | $38,727,000 | +41.7% | 780,000 | +39.3% | 5.42% | +12.7% |
| ONCE | SPARK THERAPEUTICS INC | $38,318,000 | +24.3% | 463,000 | 0.0% | 5.36% | -1.2% | |
| BLUE | Buy | BLUEBIRD BIO INC | $31,390,000 | +26.8% | 200,000 | +37.9% | 4.39% | +0.8% |
| AGIO | AGIOS PHARMACEUTICALS INC | $30,725,000 | +3.0% | 364,776 | 0.0% | 4.30% | -18.1% | |
| FATE | FATE THERAPEUTICS INC | $29,484,000 | +16.2% | 2,600,000 | 0.0% | 4.12% | -7.6% | |
| CDXS | CODEXIS INC | $29,160,000 | +30.9% | 2,025,000 | 0.0% | 4.08% | +4.1% | |
| MGTA | New | MAGENTA THERAPEUTICS INC | $27,484,000 | – | 2,035,818 | +100.0% | 3.84% | – |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $26,592,000 | -10.7% | 270,000 | +8.0% | 3.72% | -29.0% |
| VYGR | VOYAGER THERAPEUTICS INC | $22,178,000 | +4.0% | 1,135,000 | 0.0% | 3.10% | -17.3% | |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $21,692,000 | +3.6% | 3,400,000 | -11.7% | 3.03% | -17.6% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $21,696,000 | -25.1% | 480,000 | -20.0% | 3.03% | -40.5% |
| ILMN | ILLUMINA INC | $19,969,000 | +18.1% | 71,500 | 0.0% | 2.79% | -6.1% | |
| SGMO | SANGAMO THERAPEUTICS INC | $19,880,000 | -25.3% | 1,400,000 | 0.0% | 2.78% | -40.6% | |
| BOLD | AUDENTES THERAPEUTICS INC | $17,195,000 | +27.2% | 450,000 | 0.0% | 2.40% | +1.1% | |
| CRSP | Buy | CRISPR THERAPEUTICS AGnamen akt | $12,927,000 | +109.5% | 220,000 | +63.0% | 1.81% | +66.6% |
| EVH | Sell | EVOLENT HEALTH INCcl a | $11,578,000 | -26.8% | 550,000 | -50.5% | 1.62% | -41.8% |
| BLFS | New | BIOLIFE SOLUTIONS INC | $11,410,000 | – | 1,000,000 | +100.0% | 1.60% | – |
| BGNE | BEIGENE LTDsponsored adr | $10,761,000 | -8.5% | 70,000 | 0.0% | 1.50% | -27.2% | |
| OSUR | Buy | ORASURE TECHNOLOGIES INC | $10,541,000 | +160.0% | 640,000 | +166.7% | 1.47% | +106.7% |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $10,003,000 | +6.7% | 220,000 | +23.9% | 1.40% | -15.1% |
| EDIT | Buy | EDITAS MEDICINE INC | $6,390,000 | +44.6% | 178,333 | +33.8% | 0.89% | +15.1% |
| NEOG | NEOGEN CORP | $5,212,000 | +19.7% | 65,000 | 0.0% | 0.73% | -4.8% | |
| CTMX | CYTOMX THERAPEUTICS INC | $4,743,000 | -19.7% | 207,500 | 0.0% | 0.66% | -36.1% | |
| NTGN | New | NEON THERAPEUTICS INC | $4,263,000 | – | 338,345 | +100.0% | 0.60% | – |
| LOXO | New | LOXO ONCOLOGY INCput | $3,470,000 | – | 20,000 | +100.0% | 0.48% | – |
| ZLAB | ZAI LAB LTDadr | $3,139,000 | +8.9% | 135,000 | 0.0% | 0.44% | -13.4% | |
| JNCE | Sell | JOUNCE THERAPEUTICS INC | $2,873,000 | -79.8% | 375,000 | -40.9% | 0.40% | -83.9% |
| CDNA | New | CAREDX INC | $2,448,000 | – | 200,000 | +100.0% | 0.34% | – |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $2,346,000 | +109.1% | 115,000 | +91.7% | 0.33% | +66.5% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INput | $2,260,000 | – | 50,000 | +100.0% | 0.32% | – |
| BPMC | New | BLUEPRINT MEDICINES CORPcall | $635,000 | – | 10,000 | +100.0% | 0.09% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -300,000 | -100.0% | -0.31% | – |
| CELG | Exit | CELGENE CORPcall | $0 | – | -40,000 | -100.0% | -0.63% | – |
| IBB | Exit | ISHARES TRnasdaq biotech | $0 | – | -95,000 | -100.0% | -1.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2018-08-20
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
| 13F-HR | 2024-02-14 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.